成人Still病诊疗进展

doi:10.35541/cjd.20190772

Abstract

Abstract: 【Abstract】 Adult-onset Still′s disease （AOSD） is a type of systemic inflammatory disease of unknown etiology, with diverse clinical manifestations, and there are some difficulties in its diagnosis and treatment. In recent years, it has been found that some new markers, such as heme oxygenase 1, calreticulin, inflammatory cytokines and advanced glycation end products, can be used for a comprehensive assessment of the activity and severity of AOSD. Moreover, new biological agents, such as tumor necrosis factor inhibitors, interleukin-1 (IL-1) inhibitors, IL-6 inhibitors and recombinant IL-18 binding proteins, bring new hope for the treatment of AOSD. This review mainly summarizes progress in the diagnosis and treatment of AOSD.

Key words: Diagnosis, Biological markers, Therapy, Biological agents, Adult-onset Still′s disease

Yi Xiaoqing, Luo Shuaihantian, Zhang Guiying, Lu Qianjin. Diagnosis and treatment of adult-onset Still′s disease[J]. Chinese Journal of Dermatology, 2021, 54(2): 165-169.doi:10.35541/cjd.20190772

References ［55］

［1］	Masson C, Le Loet X, Liote F, et al. Comparative study of 6 types of criteria in adult Still′s disease［J］. J Rheumatol, 1996,23（3）:495⁃497.
［2］	Cush JJ, Medsger TA Jr, Christy WC, et al. Adult⁃onset Still′s disease. Clinical course and outcome［J］. Arthritis Rheum, 1987,30（2）:186⁃194. doi: 10.1002/art.1780300209.
［3］	Giacomelli R, Ruscitti P, Shoenfeld Y. A comprehensive review on adult onset Still′s disease［J］. J Autoimmun, 2018,93:24⁃36. doi: 10.1016/j.jaut.2018.07.018.
［4］	Yamaguchi M, Ohta A, Tsunematsu T, et al. Preliminary criteria for classification of adult Still′s disease［J］. J Rheumatol, 1992,19（3）:424⁃430.
［5］	Fautrel B, Zing E, Golmard JL, et al. Proposal for a new set of classification criteria for adult⁃onset still disease［J］. Medicine （Baltimore）, 2002,81（3）:194⁃200. doi: 10.1097/00005792⁃200205000⁃00003.
［6］	Lee MH, Means RT Jr. Extremely elevated serum ferritin levels in a university hospital: associated diseases and clinical significance［J］. Am J Med, 1995,98（6）:566⁃571. doi: 10.1016/s0002⁃9343（99）80015⁃1.
［7］	Fautrel B, Le Moël G, Saint⁃Marcoux B, et al. Diagnostic value of ferritin and glycosylated ferritin in adult onset Still′s disease［J］. J Rheumatol, 2001,28（2）:322⁃329.
［8］	Vignes S, Le Moël G, Fautrel B, et al. Percentage of glycosylated serum ferritin remains low throughout the course of adult onset Still′s disease［J］. Ann Rheum Dis, 2000,59（5）:347⁃350. doi: 10.1136/ard.59.5.347.
［9］	Kirino Y, Kawaguchi Y, Tada Y, et al. Beneficial use of serum ferritin and heme oxygenase⁃1 as biomarkers in adult⁃onset Still′s disease: a multicenter retrospective study［J］. Mod Rheumatol, 2018,28（5）:858⁃864. doi: 10.1080/14397595.2017.1422231.
［10］	Foell D, Roth J. Proinflammatory S100 proteins in arthritis and autoimmune disease［J］. Arthritis Rheum, 2004,50（12）:3762⁃3771. doi: 10.1002/art.20631.
［11］	Kim HA, Han JH, Kim WJ, et al. TLR4 endogenous ligand S100A8/A9 levels in adult⁃onset Still′s disease and their association with disease activity and clinical manifestations［J］. Int J Mol Sci, 2016,17（8）. doi: 10.3390/ijms17081342.
［12］	Jung SY, Park YB, Ha YJ, et al. Serum calprotectin as a marker for disease activity and severity in adult⁃onset Still′s disease［J］. J Rheumatol, 2010,37（5）:1029⁃1034. doi: 10.3899/jrheum.091120.
［13］	Mitrovic S, Fautrel B. New markers for adult⁃onset Still′s disease［J］. Joint Bone Spine, 2018,85（3）:285⁃293. doi: 10.1016/j.jbspin.2017.05.011.
［14］	Kudela H, Drynda S, Lux A, et al. Comparative study of Interleukin⁃18 （IL⁃18） serum levels in adult onset Still′s disease （AOSD） and systemic onset juvenile idiopathic arthritis （sJIA） and its use as a biomarker for diagnosis and evaluation of disease activity［J］. BMC Rheumatol, 2019,3:4. doi: 10.1186/s41927⁃019⁃0053⁃z.
［15］	Priori R, Colafrancesco S, Alessandri C, et al. Interleukin 18: a biomarker for differential diagnosis between adult⁃onset Still′s disease and sepsis［J］. J Rheumatol, 2014,41（6）:1118⁃1123. doi: 10.3899/jrheum.130575.
［16］	Shimizu M, Kizawa T, Kato R, et al. Macrophage activation syndrome in neonates born to mothers with adult⁃onset Still′s disease: perinatal effect of maternal IL⁃18［J］. Clin Immunol, 2019,207:36⁃39. doi: 10.1016/j.clim.2019.07.005.
［17］	Sun Y, Wang Z, Chi H, et al. Elevated serum levels of interleukin⁃10 in adult⁃onset Still′s disease are associated with disease activity［J］. Clin Rheumatol, 2019,38（11）:3205⁃3210. doi: 10.1007/s10067⁃019⁃04642⁃x.
［18］	Chi H, Liu D, Sun Y, et al. Interleukin⁃37 is increased in adult⁃onset Still′s disease and associated with disease activity［J］. Arthritis Res Ther, 2018,20（1）:54. doi: 10.1186/s13075⁃018⁃1555⁃6.
［19］	Shimojima Y, Kishida D, Ueno KI, et al. Characteristics of circulating natural killer cells and their interferon⁃γ production in active adult⁃onset Still disease［J］. J Rheumatol, 2019,46（10）:1268⁃1276. doi: 10.3899/jrheum.181192.
［20］	Colafrancesco S, Priori R, Valesini G. Presentation and diagnosis of adult⁃onset Still′s disease: the implications of current and emerging markers in overcoming the diagnostic challenge［J］. Expert Rev Clin Immunol, 2015,11（6）:749⁃761. doi: 10.1586/1744666X.2015.1037287.
［21］	Han JH, Ahn MH, Jung JY, et al. The levels of CXCL12 and its receptor, CXCR4, as a biomarker of disease activity and cutaneous manifestation in adult⁃onset Still′s disease［J］. Clin Exp Rheumatol, 2019,37 Suppl 121（6）:67⁃73.
［22］	Kim HA, Kim YH, Jeon YK, et al. Histopathology and expression of the chemokines CXCL10, CXCL13, and CXCR3 and the endogenous TLR⁃4 ligand S100A8/A9 in lymph nodes of patients with adult⁃onset Still′s disease［J］. Sci Rep, 2019,9（1）:7517. doi: 10.1038/s41598⁃019⁃44032⁃6.
［23］	Chen DY, Chen YM, Lin CC, et al. The potential role of advanced glycation end products （AGEs） and soluble receptors for AGEs （sRAGE） in the pathogenesis of adult⁃onset still′s disease［J］. BMC Musculoskelet Disord, 2015,16:111. doi: 10.1186/s12891⁃015⁃0569⁃3.
［24］	Hu Q, Gong W, Gu J, et al. Plasma microRNA profiles as a potential biomarker in differentiating adult⁃onset Still′s disease from sepsis［J］. Front Immunol, 2018,9:3099. doi: 10.3389/fimmu.2018.03099.
［25］	Siddiqui M, Putman MS, Dua AB. Adult⁃onset Still′s disease: current challenges and future prospects［J］. Open Access Rheumatol, 2016,8:17⁃22. doi: 10.2147/OARRR.S83948.
［26］	Colina M, Zucchini W, Ciancio G, et al. The evolution of adult⁃onset Still disease: an observational and comparative study in a cohort of 76 Italian patients［J］. Semin Arthritis Rheum, 2011,41（2）:279⁃285. doi: 10.1016/j.semarthrit.2010.12.006.
［27］	Kong XD, Xu D, Zhang W, et al. Clinical features and prognosis in adult⁃onset Still′s disease: a study of 104 cases［J］. Clin Rheumatol, 2010,29（9）:1015⁃1019. doi: 10.1007/s10067⁃010⁃1516⁃1.
［28］	Maria AT, Le Quellec A, Jorgensen C, et al. Adult onset Still′s disease （AOSD） in the era of biologic therapies: dichotomous view for cytokine and clinical expressions［J］. Autoimmun Rev, 2014,13（11）:1149⁃1159. doi: 10.1016/j.autrev.2014.08.032.
［29］	Ruscitti P, Ursini F, Cipriani P, et al. Biologic drugs in adult onset Still′s disease: a systematic review and meta⁃analysis of observational studies［J］. Expert Rev Clin Immunol, 2017,13（11）:1089⁃1097. doi: 10.1080/1744666X.2017.1375853.
［30］	Li S, Zheng S, Tang S, et al. Autoinflammatory pathogenesis and targeted therapy for adult⁃onset Still′s disease［J］. Clin Rev Allergy Immunol, 2020,58（1）:71⁃81. doi: 10.1007/s12016⁃019⁃08747⁃8.
［31］	Vitale A, Cavalli G, Colafrancesco S, et al. Long⁃term retention rate of anakinra in adult onset Still′s disease and predictive factors for treatment response［J］. Front Pharmacol, 2019,10:296. doi: 10.3389/fphar.2019.00296.
［32］	Vercruysse F, Barnetche T, Lazaro E, et al. Adult⁃onset Still′s disease biological treatment strategy may depend on the phenotypic dichotomy［J］. Arthritis Res Ther, 2019,21（1）:53. doi: 10.1186/s13075⁃019⁃1838⁃6.
［33］	Lyseng⁃Williamson KA. Anakinra in Still′s disease: a profile of its use［J］. Drugs Ther Perspect, 2018,34（12）:543⁃553. doi: 10.1007/s40267⁃018⁃0572⁃5.
［34］	Castañeda S, Atienza⁃Mateo B, Martín⁃Varillas JL, et al. Anakinra for the treatment of adult⁃onset Still′s disease［J］. Expert Rev Clin Immunol, 2018,14（12）:979⁃992. doi: 10.1080/1744666X.2018.1536548.
［35］	Hong D, Yang Z, Han S, et al. Interleukin 1 inhibition with anakinra in adult⁃onset Still disease: a meta⁃analysis of its efficacy and safety［J］. Drug Des Devel Ther, 2014,8:2345⁃2357. doi: 10.2147/DDDT.S73428.
［36］	Colafrancesco S, Priori R, Valesini G, et al. Response to interleukin⁃1 inhibitors in 140 Italian patients with adult⁃onset Still′s disease: a multicentre retrospective observational study［J］. Front Pharmacol, 2017,8:369. doi: 10.3389/fphar.2017.00369.
［37］	Kontzias A, Efthimiou P. The use of Canakinumab, a novel IL⁃1β long⁃acting inhibitor, in refractory adult⁃onset Still′s disease［J］. Semin Arthritis Rheum, 2012,42（2）:201⁃205. doi: 10.1016/j.semarthrit.2012.03.004.
［38］	Barsotti S, Neri R, Iacopetti V, et al. Successful treatment of refractory adult⁃onset still disease with canakinumab: a case report［J］. J Clin Rheumatol, 2014,20（2）:121. doi: 10.1097/RHU.0000000000000082.
［39］	Castañeda S, Martínez⁃Quintanilla D, Martín⁃Varillas JL, et al. Tocilizumab for the treatment of adult⁃onset Still′s disease［J］. Expert Opin Biol Ther, 2019,19（4）:273⁃286. doi: 10.1080/14712598.2019.1590334.
［40］	Nishina N, Kaneko Y, Kameda H, et al. The effect of tocilizumab on preventing relapses in adult⁃onset Still′s disease: a retrospective, single⁃center study［J］. Mod Rheumatol, 2015,25（3）:401⁃404. doi: 10.3109/14397595.2014.973659.
［41］	Cipriani P, Ruscitti P, Carubbi F, et al. Tocilizumab for the treatment of adult⁃onset Still′s disease: results from a case series［J］. Clin Rheumatol, 2014,33（1）:49⁃55. doi: 10.1007/s10067⁃013⁃2381⁃5.
［42］	Ma Y, Wu M, Zhang X, et al. Efficacy and safety of tocilizumab with inhibition of interleukin⁃6 in adult⁃onset Still′s disease: a meta⁃analysis［J］. Mod Rheumatol, 2018,28（5）:849⁃857. doi: 10.1080/14397595.2017.1416924.
［43］	Gabay C, Fautrel B, Rech J, et al. Open⁃label, multicentre, dose⁃escalating phase II clinical trial on the safety and efficacy of tadekinig alfa （IL⁃18BP） in adult⁃onset Still′s disease［J］. Ann Rheum Dis, 2018,77（6）:840⁃847. doi: 10.1136/annrheumdis⁃2017⁃212608.
［44］	Yang XP, Wang M, Li TF, et al. Predictive factors and prognosis of macrophage activation syndrome associated with adult⁃onset Still′s disease［J］. Clin Exp Rheumatol, 2019,37 Suppl 121（6）:83⁃88.
［45］	Ruscitti P, Iacono D, Ciccia F, et al. Macrophage activation syndrome in patients affected by adult⁃onset Still disease: analysis of survival rates and predictive factors in the gruppo italiano di ricerca in reumatologia clinica e sperimentale cohort［J］. J Rheumatol, 2018,45（6）:864⁃872. doi: 10.3899/jrheum.170955.
［46］	Mitrovic S, Fautrel B. Complications of adult⁃onset Still′s disease and their management［J］. Expert Rev Clin Immunol, 2018,14（5）:351⁃365. doi: 10.1080/1744666X.2018.1465821.
［47］	Chamseddin B, Marks E, Dominguez A, et al. Refractory macrophage activation syndrome in the setting of adult⁃onset Still disease with hemophagocytic lymphohistiocytosis detected on skin biopsy treated with canakinumab and tacrolimus［J］. J Cutan Pathol, 2019,46（7）:528⁃531. doi: 10.1111/cup.13466.
［48］	Junge G, Mason J, Feist E. Adult onset Still′s disease⁃the evidence that anti⁃interleukin⁃1 treatment is effective and well⁃tolerated （a comprehensive literature review）［J］. Semin Arthritis Rheum, 2017,47（2）:295⁃302. doi: 10.1016/j.semarthrit.2017.06.006.
［49］	Efthimiou P, Kadavath S, Mehta B. Life⁃threatening complications of adult⁃onset Still′s disease［J］. Clin Rheumatol, 2014,33（3）:305⁃314. doi: 10.1007/s10067⁃014⁃2487⁃4.
［50］	Gerfaud⁃Valentin M, Maucort⁃Boulch D, Hot A, et al. Adult⁃onset still disease: manifestations, treatment, outcome, and prognostic factors in 57 patients［J］. Medicine （Baltimore）, 2014,93（2）:91⁃99. doi: 10.1097/MD.0000000000000021.
［51］	Narváez J, Mora⁃Limiñana M, Ros I, et al. Pulmonary arterial hypertension in adult⁃onset Still′s disease: a case series and systematic review of the literature［J］. Semin Arthritis Rheum, 2019,49（1）:162⁃170. doi: 10.1016/j.semarthrit.2018.11.007.
［52］	Néel A, Wahbi A, Tessoulin B, et al. Diagnostic and management of life⁃threatening adult⁃onset Still disease: a French nationwide multicenter study and systematic literature review［J］. Crit Care, 2018,22（1）:88. doi: 10.1186/s13054⁃018⁃2012⁃2.
［53］	Masson C, Le Loët X, Lioté F, et al. Adult Still′s disease. Part II. Management, outcome, and prognostic factors［J］. Rev Rhum Engl Ed, 1995,62（11）:758⁃765.
［54］	Pouchot J, Sampalis JS, Beaudet F, et al. Adult Still′s disease: manifestations, disease course, and outcome in 62 patients［J］. Medicine （Baltimore）, 1991,70（2）:118⁃136.
［55］	Jamilloux Y, Gerfaud⁃Valentin M, Henry T, et al. Treatment of adult⁃onset Still′s disease: a review［J］. Ther Clin Risk Manag,2015,11:33⁃43. doi: 10.2147/TCRM.S64951.

[1]	Guo Lan, Jin Hongzhong. Small-molecule/biological agents in the treatment of pruritus [J]. Chinese Journal of Dermatology, 2024, 57(5): 475-478.
[2]	Lu Jiawei, Lu Yan. Paradoxical psoriasis induced by tumor necrosis factor-α inhibitors and other biological agents [J]. Chinese Journal of Dermatology, 2024, 57(5): 479-482.
[3]	China Dermatologist Association. Guidelines for the management of chronic pruritus （2024） [J]. Chinese Journal of Dermatology, 2024, 57(5): 387-399.
[4]	Mycobacteriosis Research Group, China “Belt and Road” Dermatology Alliance, Division of Dermatology and STI Diagnosis, Chinese Association on Leprosy. Expert consensus on the clinical diagnosis and treatment of cutaneous tuberculosis in China （2024） [J]. Chinese Journal of Dermatology, 2024, 57(5): 426-434.
[5]	China Dermatologist Association, Combination of Traditional and Western Medicine Dermatology. Diagnosis and treatment of erythrodermic psoriasis: a Chinese expert consensus statement （2024） [J]. Chinese Journal of Dermatology, 2024, 57(5): 409-417.
[6]	Mycology Group, Combination of Traditional and Western Medicine Dermatology, Chinese Antifungal-Resistant Dermatophytosis Expert Consensus Group. Expert consensus on the diagnosis, treatment, prevention and control of antifungal-resistant dermatophyte infections in China （2024） [J]. Chinese Journal of Dermatology, 2024, 57(5): 418-425.
[7]	Yue Shuzhen, Shu Ye, Luo Yangyang, Li Keyao, Zhang Yuanyuan, Tang Jianping, Wei Zhu. Efficacy and safety of omalizumab in the treatment of chronic urticaria in children: a retrospective study [J]. Chinese Journal of Dermatology, 2024, 57(4): 354-358.
[8]	Liu Yi, Qu Ying, Lei Wenzhi, Liu Xiaogang, Pan Weihua, Zhang Chao. Clinical efficacy of salt-packing therapy in the treatment of pyogenic granuloma [J]. Chinese Journal of Dermatology, 2024, 0(4): 20230553-e20230553.
[9]	Zhang Dimin, Cao Cheng, Zhou Miaoni, Sheng Anqi, Lin Fuquan, Xu Ai′e. Analysis of disease control rate and its influencing factors in patients with progressive non-segmental vitiligo after combined treatment with compound betamethasone injection [J]. Chinese Journal of Dermatology, 2024, 57(4): 350-354.
[10]	Wang Yimeng, Wu Wenting, Zhang Qian, Zhang Chunlei, Li Weiwei. Clinical and pathological diagnoses of 389 patients with primary solid tumors localized in the perianal and external genitalia regions [J]. Chinese Journal of Dermatology, 2024, 57(4): 316-323.
[11]	Ge Xinhong, Ma Yingdong, Jiao Yaning, Liu Lingling, Zhou Mei, Zi Wei, Li Bowen. Analysis of efficacy and safety of 532-nm picosecond laser in the treatment of early-stage facial seborrheic keratosis [J]. Chinese Journal of Dermatology, 2024, 57(4): 359-362.
[12]	Yan Rufan, Liao Jieyue, Guo Ziyu, Yao Nan, Zhou Wenyu, Luo Shuaihantian, Zhang Guiying, Zhao Ming. Pathogenesis and targeted therapy of pemphigus [J]. Chinese Journal of Dermatology, 2024, 57(4): 374-378.
[13]	Ding Rui, Zhang Weiliang, Li Jing, Chen Yujia, Li Junying. Dupilumab for the treatment of five cases of refractory endogenous hyperkeratotic hand-foot eczema [J]. Chinese Journal of Dermatology, 2024, 0(4): 20230429-e20230429.
[14]	Dai Yeqin, Song Xiuzu. Application of hair follicle transplantation and follicular cell suspension transplantation in the treatment of vitiligo [J]. Chinese Journal of Dermatology, 2024, 0(3): 20230274-e0230274.
[15]	Yao Wo, Wang Huiying. Lanadelumab in the treatment of hereditary angioedema: a systematic review of clinical trials [J]. Chinese Journal of Dermatology, 2024, 0(3): 20230378-e20230378.

Diagnosis and treatment of adult-onset Still′s disease

PDF

PDF (Mobile)

Knowledge

Abstract

Cite this article

share this article

References ［55］

Related Articles 15

Metrics

Comments

Recommended 10